{"Clinical Trial ID": "NCT00331552", "Intervention": ["INTERVENTION 1:", "Phase I: Cyclophosphamide, Doxil, Trastuzumab", "Patients receive oral cyclophosphamide once daily on days 1 to 28 and pegylated doxorubicin HCl liposomal IV over 90 minutes on day 1. Treatment is repeated every 4 to 6 weeks in the absence of disease progression or unacceptable toxicity.", "Pegylated doxorubicin hydrochloride: given IV", "cyclophosphamide: administered orally", "Trastuzumab: under IV"], "Eligibility": ["Incorporation criteria:", "Patients must meet the following conditions: (a) a measurable disease according to RECIST criteria; x-rays, scans or physical examinations used to evaluate tumours must have been performed within 30 days prior to registration; any non-measurable disease must be evaluated within 42 days prior to registration; (b) a non-measurable disease, but the MUC-1 antigen (CA 27-29 or CEA) rate is > 2X UCL-1 AND the MUC-1 antigen has been identified as having increased 1.5X prior to registration; x-rays, scans or other non-measurable disease assessment tests must have been performed within 42 days prior to registration.", "ECOG Performance Status = < 2", "ANC >= 1,500 cells/mm^3", "Number of platelets >= 100,000 cells/mm^3", "Hemoglobin >= 9.0 g/dL", "Creatinine = < 2.5 mg/dL", "In the absence of liver metastases, AST/ALT, alkaline phosphatase and total bilirubin should not exceed 2 x upper limit of normal (i.e., should be < 2 x upper limit of normal)", "In the presence of liver metastases, AST/ALT, alkaline phosphatase and total bilirubin should not exceed 3 x upper limit of normal (i.e., should be < 3 x upper limit of normal)", "A 2-day MUGA or echocardiogram analysis indicating an ejection fraction of >= 50% within 42 days prior to the first dose of the study drug (the method used at baseline should be used for further monitoring).", "\u2022 Use an adequate contraceptive method (e.g. abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during treatment and for three months after completion of treatment if reproductive potential", "To be informed of the investigational nature of this study and to provide written informed consent in accordance with institutional and federal guidelines before considering specific screening procedures.", "- Exclusion criteria:", "Pregnant or lactating women", "History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL or to Doxil components", "Patients who are HER2-neu positive for heart disease who would prevent the use of Doxil or Herceptin are not eligible, including active heart disease (i.e., angina that requires the use of anti-anginal drugs, cardiac arrhythmia requiring medication, severe conduction abnormality, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy on EKG, uncontrolled hypertension [diastolic > 100 mm/Hg or systolic > 200 mm/hg], current use of digitalis or beta blockers for CHF, clinically significant pericardial effusion) and history of heart disease (i.e., myocardial infarction documented as a clinical diagnosis or by EKG or any other test, documented congestive heart failure, documented cardiomyopathy, documented arrhythmia or cardiac valvular disease requiring medication or being medically significant)", "The cumulative dose of anthracycline is greater than 360 mg/m^ 2 for doxorubicin or 540 mg/m^2 for epirubicin AND the interval between discontinuation of anthracycline and diagnosis of metastatics is less than 12 months; b) If anthracycline is administered for metastatics: The cumulative dose of anthracycline is greater than 360 mg/m^2 for doxorubicin or 540 mg/m^2 for epirubicin AND patient disease progresses on anthracycline administered as palliative therapy", "With the exception of the following, no other malignancy is permitted: ipsilateral synchronous breast cancer of the same subtype (ER/PR, HER-2/neu), skin cancer of basal or squamous cells, cervical cancer in situ or other stage I or II cancer whose patient has not attained for at least 5 years.", "Any life-threatening illness other than the malignancy for which they are treated", "Mental diseases", "Have a life expectancy of less than 4 months", "\u2022 Lack of willingness to participate or inability to comply with the protocol for the duration of the study"], "Results": ["Performance measures:", "Maximum tolerated dose and optimal tolerated dose of pegylated doxorubicin liposomal hydrochloride (Doxil) when administered in combination with cyclophosphamide (phase I)", "The dose level at which 2 or more patients develop grade 3 or higher treatment-related toxicity requires dose adjustment after the first treatment.", "Time limit: up to 24 weeks", "Results 1:", "Title of the arm/group: Phase I: Cyclophosphamide, Doxil, Trastuzumab", "Description of the arm/group: Patients receive oral cyclophosphamide once daily on days 1 to 28 and pegylated doxorubicin HCl liposomal IV over 90 minutes on day 1. Treatment is repeated every 4 to 6 weeks in the absence of disease progression or unacceptable toxicity.", "Pegylated doxorubicin hydrochloride: given IV", "cyclophosphamide: administered orally", "Trastuzumab: under IV", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measurement: mg/m^2 30"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/27 (0.00 per cent)"]}